Stock 4572 CARNA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Carna Biosciences, Inc.

Equities

4572

JP3220550002

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
428 JPY -2.28% Intraday chart for Carna Biosciences, Inc. -2.73% -18.01%
Mar. 07 Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement CI
2023 Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement
CI
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.
CI
Carna Biosciences, Inc. announced that it expects to receive Ñ11.209315 million in funding from Cantor Fitzgerald & Co.
CI
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
CI
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases
MT
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc
CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021
CI
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021
CI
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.
CI
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.
CI
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020
CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020
CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
CI
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020
CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020
CI
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
CI
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019
CI
Open Orphan Signs Contract with Carna Bioscience
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4572 Stock
  4. News Carna Biosciences, Inc.